Cisplatin News and Research

RSS

Study supports future possibility of personalized medicine for cervical cancer

Doctors at Washington University School of Medicine in St. Louis have shown that testing cervical tumors before treatment for vulnerability to chemotherapy predicts whether patients will do well or poorly with standard treatment.

1 Jun 2013

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

A team of UT Arlington researchers has identified two ruthenium-based complexes they believe could pave the way for treatments that control cancer cell growth more effectively and are less toxic for patients than current chemotherapies.

30 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Study underscores new paradigm in cancer therapy

In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers.

16 May 2013

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.

15 May 2013

Study: Combination of chemotherapy and nerve-protecting agents can prevent anemia

Cancer chemotherapy can cause peripheral neuropathy-nerve damage often resulting in pain and muscle weakness in the arms and legs. Now, researchers at Albert Einstein College of Medicine of Yeshiva University have discovered that chemo also induces an insidious type of nerve damage inside bone marrow that can cause delays in recovery after bone marrow transplantation.

6 May 2013

Clinical study shows association between results of ChemoFx and RFS of cervical cancer patients

A clinical study reporting an association between the results of the ChemoFx chemoresponse assay and recurrence free survival of cervical cancer patients has been accepted for publication by Gynecologic Oncology.

30 Apr 2013

Two abstracts related to Advaxis' ADXS-HPV selected for poster presentation at ASCO meeting

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts related to ADXS-HPV (ADXS11-001), the Company's lead clinical stage product candidate, have been selected for poster presentation at the 2013 American Society of Clinical Oncology Annual Meeting in Chicago, IL, from May 31 - June 4, 2013, at the McCormick Place Convention Center.

18 Apr 2013

Preclinical studies show bladder cancers, mesotheliomas respond to treatment with ADI-PEG 20

Scientists from academic institutions reported at the 2013 annual American Association for Cancer Research meeting, results from preclinical studies which showed that certain bladder cancers and mesotheliomas have metabolic changes and are more likely to respond to treatment with ADI-PEG 20 (pegylated arginine deiminase) if they are deficient in the enzyme, argininosuccinate synthetase.

18 Apr 2013

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

11 Apr 2013

PARP inhibitors can be novel treatment strategy for cisplatin-resistant cancer

Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.

3 Apr 2013

Study on neoadjuvant cisplatin-based chemotherapy presented at 28th Annual EAU Congress

At the 28th Annual EAU Congress currently ongoing in Milan until Tuesday, W. Tan and colleagues presented their study on neoadjuvant cisplatin-based chemotherapy which showed that epigenetic changes are potential key drivers in the development of chemo resistance in bladder cancer.

18 Mar 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Researchers identify miR-506 as potential therapeutic candidate for metastatic ovarian cancer

Researchers employed an extensive analysis of genomic information to identify a new, high-risk cohort of ovarian cancer patients, characterize their tumors, find a potential treatment and test it in mouse models of the disease.

11 Feb 2013

Positive results from NCI-sponsored bevacizumab trial on cervical cancer

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial.

10 Feb 2013

BSD Medical announces results from BSD-2000 hyperthermia system study on pancreatic cancer

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced the publication of results from a clinical study on advanced pancreatic cancer using the BSD-2000 Hyperthermia System (BSD-2000).

6 Feb 2013

UPCI researchers uncover new technique to stop growth of cancer cells

University of Pittsburgh Cancer Institute (UPCI) researchers have uncovered a technique to halt the growth of cancer cells, a discovery that led them to a potential new anti-cancer therapy.

5 Feb 2013

University of Kentucky professor to continue research into ruthenium-based cancer drugs

University of Kentucky assistant professor of chemistry Edith "Phoebe" Glazer has received an American Cancer Society Research Scholar Grant for $715,000 over four years to continue her research into ruthenium-based cancer drugs. These compounds are less toxic to healthy cells than a similar and widely used inorganic drug.

1 Feb 2013

Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).

17 Jan 2013

$Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer$

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.

3 Jan 2013